![](https://investorshub.advfn.com/uicon/335383.png?cb=1609924894)
Monday, October 15, 2012 8:32:14 AM
As I was reading the transcript I got the feeling that the FDA panel really is looking at this from a very different perspective.
They seem to be getting the message that we have a lot of patients without any viable treatment options. Ampligen has been used successfully for many years in selected patients without serious risk. The risk to benefit ratio would seem to favor approval this time around!
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM